{"schema_version":"secwatch.filing_event.v1","accession":"0001398733-26-000029","form_type":"8-K","ticker":"AQST","cik":"0001398733","company_name":"Aquestive Therapeutics, Inc.","filed_at":"2026-05-13T20:04:40+00:00","discovered_at":"2026-05-13T20:06:00.811128+00:00","generated_at":"2026-05-13T22:14:10.893621+00:00","sec_items":["1.01","3.02","1.02","2.02","2.03","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Aquestive Q1 revenue up 66% to $14.4M; secures $150M Oaktree debt facility","bullets":["Q1 total revenue $14.4M (+66% YoY); license/royalty $5.4M, manufacture/supply $8.8M.","R&D expenses down to $4.2M from $5.4M; SG&A $11.0M vs $19.1M (prior year included $4.3M PDUFA fee).","Reaffirmed Anaphylm NDA resubmission in Q3 2026 after FDA Type A meeting alignment on studies.","Entered $150M Oaktree debt facility: $55M funded, $20M available on FDA approval, $25M on sales milestone.","Used proceeds to repay $45M existing notes; expects $150M cash for Anaphylm launch if approved in 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001398733-26-000029","json":"https://secwatch.observer/filing/0001398733-26-000029.json","markdown":"https://secwatch.observer/filing/0001398733-26-000029.md","text":"https://secwatch.observer/filing/0001398733-26-000029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1398733/000139873326000029/0001398733-26-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1398733/000139873326000029/aqst-20260512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-13T22:14:10.893621+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8a91a4d07af8760faec34186b95a333c95f9a64b","claim":"Aquestive Therapeutics, Inc. incurred credit facility of up to $150.0 million with Oaktree Fund Administration, LLC, as administrative agent, and certain funds managed by Oaktree Capital Management, L.P. as Lenders at three-month SOFR (with a floor of 2.75%) plus 6.25% maturing five years from the closing date.","evidence_excerpt":"On May 12, 2026 (the “Effective Date”), Aquestive Therapeutics, Inc. (the “Company”) entered into a five-year term loan facility of up to $150.0 million (the “Term Loan”), consisting of a term loan in an aggregate principal amount of $55.0 million that was funded on the Effective Date (the “Tranche A Term Loan”), a term loan in an aggregate principal amount of $20.0 million available subject to certain terms and conditions (the “Tranche B Term Loan”), a term loan in an aggregate principal amount of $25.0 million available subject to certain terms and conditions (the “Tranche C Term Loan”), and a term loan advance available upon the mutual consent of the Lenders and subject to certain terms and conditions in an aggregate principal amount of up to $50.0 million (the “Tranche D Term Loan”), pursuant to a credit agreement and guaranty, dated as of the Effective Date (the “Credit Agreement”), with Oaktree Fund Administration, LLC, a Delaware limited liability company, as administrative agen","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1398733/000139873326000029/0001398733-26-000029-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"credit facility"},{"label":"Principal","value":"up to $150.0 million"},{"label":"Counterparty","value":"Oaktree Fund Administration, LLC, as administrative agent, and certain funds managed by Oaktree Capital Management, L.P. as Lenders"},{"label":"Rate","value":"three-month SOFR (with a floor of 2.75%) plus 6.25%"},{"label":"Maturity","value":"five years from the closing date"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}